The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.c

Pleural thickening - Fibrothorax

Publications

Tintner R, Manian P, Gauthier P, Jankovic J

Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.

Archives of neurology. 2005;62(8):1290-5

Agarwal P, Fahn S, Frucht SJ

Diagnosis and management of pergolide-induced fibrosis.

Movement disorders : official journal of the Movement Disorder Society. 2004;19(6):699-704

Müller T, Fritze J

Fibrosis associated with dopamine agonist therapy in Parkinson's disease.

Clinical neuropharmacology. 2003;26(3):109-11

Bleumink GS, van der Molen-Eijgenraam M, Strijbos JH, Sanwikarja S, van Puijenbroek EP, Stricker BH

Pergolide-induced pleuropulmonary fibrosis.

Clinical neuropharmacology. 2002;25(5):290-3

Danoff SK, Grasso ME, Terry PB, Flynn JA

Pleuropulmonary disease due to pergolide use for restless legs syndrome.

Chest. 2001;120(1):313-6

Shaunak S, Wilkins A, Pilling JB, Dick DJ

Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide.

Journal of neurology, neurosurgery, and psychiatry. 1999;66(1):79-81